Sirnaomics Ltd

Sirnaomics Ltd an RNA therapeutics biopharmaceutical company focuses on the discovery and development of product candidates for indications with medical needs in the United Sates and the Peoples Republic of China Its lead product candidates include STP705 for the treatment cutaneous squamous cell carcinoma in situ basal cell carcinoma cholangiocarcinoma hepatocellular carcinoma liver metastases etc keloid scarless healing hypertrophic scarring and fat sculpting The companys lead product candidates also comprise STP707 to treat cholangiocarcinoma hepatocellular carcinoma liver metastases etc metastatic cutaneous squamous cell carcinoma nonsmall cell lung cancer liver fibrosis and lung fibrosis It also develops STP355 for the treatment of pan cancer STP369 to treat head and neckbladder cancer STP779 for the treatment of liverlungpancreatic cancer STP902 to treat breast cancer STP702 for the treatment of influenza STP908 to treat COVID19 RIM730 COVID19 vaccine STP909 for the treatment of HPVcervical cancer and STP122G for thrombotic disorders In addition the company is developing STP125G to treat hypertriglyceridemia STP144G for the treatment of complementmediated diseases STP133G for cardiometabolic and STP155G for the treatment hepatitis B virus Sirnaomics Ltd was founded in 2007 and is headquartered in Gaithersburg Maryland